肝细胞癌治疗方式对门静脉压力的影响.

Portal hypertension ( PH) on the basis of liver cirrhosis is a common complication of hepatocellular carcinoma ( HCC), and it is also a key factor affecting treatment decisions and prognosis. Different treatment modalities for HCC may have different effects on portal ve-nous pressure. Through a literature review, it is concluded that hepatectomy,, repeated transcatheter arterial chemoembolization, oxaliplatin chemotherapy, and lenvatinib can lead to the increase in portal venous pressure, while sorafenib and regorafenib have been proved to reduce portal venous pressure within a shod teen in clinical trials and/or animal experiments. There are also reports on the effect of novel combination treatment regimens ( such as atezolizumab combined with bevacizumab) and newly marketed first - line or second - line targeted drugs for HCC ( such as donafenib, apatinib, and anlotinib) on portal hypertension - related complications including gastrointestinal bleeding in related clinical trials, but further studies are needed to investigate their overall effect on portal venous pressure. [ABSTRACT FROM AUTHOR]